VTYX - Company ID 0001851194
The table below shows Ventyx Biosciences, Inc.'s balance sheet line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash & equivalents | $27.26M | $51.58M | $64.82M | $70.79M |
| Short-term investments | $190.06M | $200.64M | $253.12M | $187.78M |
| Receivables | - | - | - | - |
| Inventory | - | - | - | - |
| Total current assets | $229.63M | $264.35M | $330.69M | $263.02M |
| Property, plant & equipment | $614.00K | $762.00K | $407.00K |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $254.00K |
| Goodwill | - | - | - | - |
| Total assets | $276.56M | $277.69M | $371.40M | $291.48M |
| Accounts payable | $3.13M | $5.76M | $6.43M | $4.66M |
| Total current liabilities | $12.78M | $22.27M | $16.36M | $12.28M |
| Long-term debt | - | - | - | - |
| Total liabilities | $22.52M | $33.77M | $17.50M | $12.28M |
| Retained earnings | -$554.31M | -$419.19M | -$226.22M | -$117.80M |
| Total equity | $254.04M | $243.92M | $353.89M | $279.20M |